ScottBenjaminSchneiderMD

Physician

Dr. Schneider is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
210 Se 136th Ave
Vancouver, WA 98684
Phone+1 360-944-9889

Fax+1 360-944-9686

UCLA David Geffen School of Medicine/UCLA Medical CenterChief Residency, Radiation Oncology, 1995 - 1996
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Radiation Oncology, 1992 - 1995
California Pacific Medical CenterInternship, Internal Medicine, 1991 - 1992
David Geffen School of Medicine at UCLAClass of 1991
University of California, San DiegoBA, Biochemistry/Cell Biology, 1983 - 1987

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Alpha Omega Alpha 1991
Outstanding Graduate Student UCLA, 1991
Graduated Summa Cum Laude 1987
Outstanding Academic Achievement Stafford L. Warren Medal
Top Medical Graduate Hewlett Packard
Medical School Class Treasurer, Junior and Senior years
Regents Scholar 1985-1987
Caledonian Honor Society 1985-1987
Join now to see all

PubMed

9 citations
The prognostic value of PSA levels in radiation therapy of patients with carcinoma of the prostate: the UCLA experience 1988-1992.
Scott B. Schneider, Victor G. Schweitzer, Robert G. Parker, Paul W. Bycott
American Journal of Clinical Oncology. 1996-02-01

Journal Articles

The Prognostic Value of PSA Levels in the Radiation Therapy of Patients with Carinoma of the Prostate: The UCLA Experience 1988-1992.
Scott B. Schneider, M.D., Victor G. Schweitzer, M.D., Robert Parker, M.D. and Paul W. Bycott, M.P.H, American Journal of Clin. Oncol. Vol 19, No. 1

Books/Book Chapters

Cytokines, Cellular & Molecular Therapy, Vol. 5.
Chapter: Filgrastim (r-metHuG-CSF) and its potential use in the reduction of radiation-induced oropharyngeal mucositis: An interim look at a randomized, double-blind, placebo controlled trial
Page 175 - 180Scott B. Schneider, Russell D. Nishimura, Robert P. Zimmerman, Luu Tran, Josephine Shiplacoff, Marcia Tormey, Richard Contreras and Guy F. Juillard

Abstracts/Posters

The Prognostic Value of PSA Levels in the Radiation Therapy of Patients with Carinoma of the Prostate: The UCLA Experience 1988-1992.
Scott B. Schneider, M.D., Victor G. Schweitzer, M.D., Robert Parker, M.D. and Paul W. Bycott, M.P.H, American Association of Cancer Research, Toronto, Canada

Lectures

The Prognostic Value of PSA Levels in the Radiation Therapy of Patients with Carinoma of the Prostate: The UCLA Experience 1988-1992.
Los Angeles, CA, 1994, San Diego, CA, 1996
Risk of Second Malignancy Based on Treatment Modality in Hodgkin’s Disease.
UCLA Resident Seminar, Los Angeles, CA
Performed assays determining the presence/absence of antibodies to synthetic epitopes of Human Papilloma Virus protein in women with/without known cervical cancer.
Stanford University
G-CSF and Reduction of Radiation Induced Oropharyngeal Mucositis.
Los Angeles, CA, 1995, Seoul, Korea, 1996
Join now to see all